Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders

Table 1 Baseline characteristics of chronic hepatitis C patients with (group A) and without (group B) psychiatric disorders, %, n

Parameter	All patients (n = 14272)		Group A (n = 942)	Group B (n = 13330)	P value
Age, mean (min-max yr)	51.2 (18-92)		50.8 (19-90)	51.2 (18-92)	0.599 (U = 6216478)
Men/women	49.3/50.7 (7035/7237)		54.9/45.1, 507/435	49.0/51.0, 6528/6802	0.004 (χ2 = 8.3)
BMI, mean (SD)	26.2 (4.5)		26.9 (5.1)	26.1 (4.5)	0.0001 (U = 5811710)
BMI ≥ 30	17.4 (2486)		23.9 (225)	17.0 (2261)	< 0.0001 (χ2 = 29.4)
Comorbidities
Hypertension	32.0 (4567)		34.4 (324)	31.8 (4243)	0.103 (χ2 = 2.6)
Diabetes	11.3 (1614)		13.0 (122)	11.2 (1492)	0.100 (χ2 = 0.5)
Renal disease	3.8 (543)		3.4 (32)	3.8 (511)	0.498 (χ2 = 0.5)
Autoimmune disease	2.1 (304)		2.0 (19)	2.1 (285)	0.803 (χ2 = 0.06)
Non-HCC tumor	2.0 (279)		2.1 (20)	1.9 (259)	0.700 (χ2 = 0.15)
ALT (IU/L), median (IQR)	58.0 (37.0-97.0)		59.0 (36.0-96.0)	58.0 (37.0-97.0)	0.581 (U = 6204221)
Albumin (g/dL), median (IQR)	4.1 (3.8-4.4)		4.1 (3.8-4.4)	4.1 (3.8-4.4)	0.633 (U = 6222478)
Bilirubin (mg/dL), median (IQR)	0.6 (0.5-0.9)		0.6 (0.5-0.9)	0.6 (0.5-0.9)	0.060 (U = 6050856)
Hemoglobin (g/dL), median (IQR)	14.5 (13.4-15.5)		14.4 (13.4-15.4)	14.5 (13.4-15.6)	0.307 (U = 6120464)
Platelets (× 1000/μL), median (IQR)	197.0 (146.0-244.0)		190.0 (136.0-240.0)	197.0 (146.0-244.0)	0.01 (U = 597757)
Creatinine (mg/dL), median (IQR)	0.8 (0.7-0.9)		0.8 (0.7-0.9)	0.8 (0.7-0.9)	0.798 (U = 6101372)
HCV RNA, × 106 IU/mL, median (IQR)	0.97 (0.32-2.53)		1.17 (0.38-3.0)	0.96 (0.31-2.48)	0.0005 (U = 5856849)

The reported P value relates to Pearson’s chi-square test (or Fisher’s exact test if the number of observations in a category was less than 10) or the Mann-Whitney U test. BMI: Body mass index; ALT: Alanine transaminase; HCC: Hepatocellular carcinoma; IQR: Interquartile range; HCV: Hepatitis C virus; RNA: Ribonucleic acid.